Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppression: evolution in practice and trends, 1994-2004.

H-U Meier-Kriesche1, S Li, R W G Gruessner

  • 1University of Florida, Gainesville, FL, USA. meierhu@medicine.ufl.edu

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|April 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

We Need to Take the Next Step.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Utilization of Deceased Donor Kidneys to Initiate Living Donor Chains.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Planning for Uncertainty and Fallbacks Can Increase the Number of Transplants in a Kidney-Paired Donation Program.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same journal

Alpha-Gal Syndrome: Unrecognized Risks of a Tick-Bite-Associated Allergy in Transplantation and Cellular Therapy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Comment on "Role of social determinants and outcomes of patients with alcohol-associated liver disease referred for early liver transplantation: A multicenter analysis".

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Donor Acute Kidney Injury Is Not Associated With Inferior Outcomes After Simultaneous Pancreas-Kidney Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

Human Biopsy-Defined IRI-Selective Reperfusion Signature Prioritizes Reperfusion-Timed MEK Inhibition After DCD Liver Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same journal

OPERATIONAL TOLERANCE FOLLOWING INTESTINAL TRANSPLANTATION: A CASE REPORT WITH COMPREHENSIVE IMMUNE FOLLOW-UP FROM TRANSPLANT DAY TO THREE YEARS POST-IMMUNOSUPPRESSION WITHDRAWAL.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
See all related articles

Immunosuppression strategies in solid-organ transplantation have evolved, with increased antibody induction therapy and a shift from cyclosporine to tacrolimus. Acute rejection rates have declined, particularly in kidney recipients.

Area of Science:

  • Nephrology
  • Immunology
  • Transplant Surgery

Background:

  • Solid-organ transplantation outcomes are significantly influenced by immunosuppression management.
  • Recent advancements in immunosuppressive agents and regimens have reshaped post-transplant care strategies.

Observation:

  • Analysis of OPTN/SRTR data reveals key trends in immunosuppression practices over the past decade.
  • Increasing use of antibody induction therapy across various solid organs, with highest adoption in kidney and pancreas transplants.
  • Tacrolimus/mycophenolate mofetil combination is a prevalent discharge regimen for pancreas transplant recipients.

Findings:

  • A notable transition from cyclosporine to tacrolimus as the preferred calcineurin inhibitor for maintenance therapy.
  • Steroid-avoidance and withdrawal protocols are gaining traction, though corticosteroids remain common.

Related Experiment Videos

  • A significant decrease in the incidence of acute rejection episodes within the first year post-transplant, especially for kidney recipients.

    • Implications:

    • These evolving immunosuppression strategies may contribute to improved long-term graft survival and reduced rejection rates.
    • The shift towards newer agents and protocols highlights a move towards more personalized and potentially less toxic immunosuppression.
    • Continued monitoring and research are essential to optimize immunosuppression regimens for diverse solid-organ transplant recipients.